Related Experiment Videos
[Midazolam as a premedicant for trigeminal nerve blocks]
H Iida1, M Takenaka, T Tanahashi
1Department of Anesthesiology, Gifu University School of Medicine.
Masui. the Japanese Journal of Anesthesiology
|October 1, 1991
Summary
Midazolam effectively reduces discomfort and recall during painful trigeminal nerve blocks. This study found the 0.1 mg.kg-1 dose safe and beneficial for patients undergoing nerve blocks.
Area of Science:
- Anesthesiology
- Neurology
- Pharmacology
Background:
- Trigeminal neuralgia treatment often involves nerve blocks, which can be painful and uncomfortable for patients.
- Effective pain management and patient comfort are crucial during invasive procedures.
Purpose of the Study:
- To evaluate the efficacy and safety of midazolam as a premedicant for trigeminal nerve blocks.
- To determine the optimal dosage of midazolam for reducing procedural discomfort and recall.
Main Methods:
- A randomized controlled trial involving 19 patients undergoing trigeminal nerve blocks.
- Patients received midazolam (0.05 mg.kg-1 or 0.1 mg.kg-1) or a saline placebo prior to the procedure.
- Patient recall and discomfort levels were assessed the following day.
Main Results:
- The group receiving 0.1 mg.kg-1 midazolam reported significantly less discomfort and procedural recall.
- No serious adverse effects were observed in patients administered midazolam.
- Midazolam demonstrated a favorable safety profile at the tested dosages.
Conclusions:
- Midazolam is a safe and effective premedicant for trigeminal nerve blocks.
- The 0.1 mg.kg-1 dosage of midazolam significantly improves patient experience during the procedure.
- Premedication with midazolam can enhance patient comfort and reduce anxiety during uncomfortable medical interventions.